2019年

Yamauchi J, Yamano Y, Yuzawa K.
Risk of Human T-cell Leukemia Virus Type 1 Infection in Kidney Transplantation.
N Engl J Med, 380(3):296-298, 2019.

Katsuya H, Islam S, Tan BJY, Ito J, Miyazato P, Matsuo M, Inada Y, Iwase SC, Uchiyama Y, Hata H, Sato T, Yagishita N, Araya N, Ueno T, Nosaka K, Tokunaga M, Yamagishi M, Watanabe T, Uchimaru K, Fujisawa JI, Utsunomiya A, Yamano Y, Satou Y.
The Nature of the HTLV-1 Provirus in Naturally Infected Individuals Analyzed by the Viral DNA-Capture-Seq Approach.
Cell Rep, 29(3):724-735, 2019.

Yamaguchi I, Furusawa Y, Kawaguchi T, Yagishita N, Tanzawa K, Yamano Y, Matsuda F.
Establishment of a Comprehensive Information Infrastructure and a Support Organization for Rare Disease Research in Japan (RADDAR-J).
Stud Health Technol Inform, 264:1080-1083, 2019.

Tsutsumi S, Sato T, Yagishita N, Yamauchi J, Araya N, Hasegawa D, Nagasaka M, Coler-Reilly A, Inoue E, Takata A, Yamano Y.
Real-World Clinical Course of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in Japan.
Orphanet Journal of Rare Diseases, 14(1):227, 2019.

Tamaki K, Sato T, Tsugawa J, Fujioka S, Yagishita N, Araya N, Yamauchi J, Coler-Reilly A, Nagasaka M, Hasegawa Y, Yamano Y, Tsuboi Y.
Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.
Front Microbiol, 10:2110, 2019.

Morio Y, Izawa KP, Omori Y, Katata H, Ishiyama D, Koyama S, Yamano Y.
The Relationship between Walking Speed and Step Length in Older Aged Patients.
Diseases, 7(1), 2019.

Furusawa Y, Yamaguchi I, Yagishita N, Tanzawa K, Matsuda F, Yamano Y, RADDAR‐J Research and Development Group.
National platform for Rare Diseases Data Registry of Japan.
Learn Health Sys, e10080, 2019.

Nagasaka M, Ou SI.
Neuregulin 1 Fusion-Positive NSCLC.
J Thorac Oncol, 14(8):1354-1359, 2019.

Sukari A, Nagasaka M, Alhasan R, Patel D, Wozniak A, Ramchandren R, Vaishampayan U, Weise A, Flaherty L, Jang H, Kim S,Gadgeel S.
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors:A Retrospective Analysis of Real-life Experience at a Single Institution.
Anticancer Res, 39(2):781-790, 2019.

Sukari A, Abdallah N, Nagasaka M.
Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
Crit Rev Oncol Hematol, 136:1-12, 2019.

Sukari A, Nagasaka M, Diab M, Al Sibai K, Atassi B, Elayoubi JA, Kim S, Küçük Ö.
Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients.
Clin Otolaryngol,  44(4):639-643, 2019.

山内淳司、山野嘉久、湯沢賢治.
腎移植におけるHTLV-1感染のリスク.
移植, 54(6):305-307, 2019.

山内淳司、山野嘉久.
HAMの病態とHTLV-1感染細胞の異常.
細胞, 51(10):20-23, 2019.

山野嘉久.
HTLV-1関連脊髄症.
内科学書　改訂第9版.
総編集：南学　正臣, 386-387, 2019年8月30日, 中山書店.

山野嘉久, 他：「HTLV-1関連脊髄症（HAM）診療ガイドライン2019」作成委員会.
HTLV-1関連脊髄症（HAM）診療ガイドライン2019.
編集：「HTLV-1関連脊髄症（HAM）診療ガイドライン2019」作成委員会,
監修：日本神経学会, 日本神経治療学会, 日本神経免疫学会, 日本神経感染症学会, 日本HTLV-1学会, 日本移植学会.
1-181, 2019年6月5日, 南江堂.

山野嘉久.
15 HTLV-1関連脊髄症 [指定難病26]．
指定難病ペディア2019、水澤英洋、五十嵐　隆、北川泰久、高橋和久、弓倉　整　監修・編集．95-97、日本医師会、東京、2019.

山野嘉久.
HTLV-1関連脊髄症（HAM）に対する新規治療法.
Annual Review 神経2019, 149-154, 2019.